Talquetamab, marketed under the brand name Talvey, is FDA approved. It received approval for the treatment of adults with multiple myeloma.

Izervay, which is the brand name for avacincaptad pegol, received FDA approval on August 4, 2023.

Zuranolone, marketed under the brand name Zurzuvae, is approved by the FDA for the treatment of postpartum depression (PPD) in adults.

Lotilaner ophthalmic, marketed under the brand name Xdemvy, has been approved by the FDA for the treatment of Demodex blepharitis.

Donislecel, branded as Lantidra, was approved by the FDA on June 28, 2023. It represents a significant development in the treatment of type 1 diabetes.

Rozanolixizumab, marketed under the brand name Rystiggo, was approved by the FDA on June 26, 2023.

Ritlecitinib, marketed under the brand name Litfulo, received FDA approval on June 23, 2023, specifically for the treatment of severe alopecia areata.

Delandistrogene moxeparvovec, known by the brand name Elevidys, received FDA approval for the treatment of Duchenne muscular dystrophy in children on June 22, 2023.

Vyvgart Hytrulo received FDA approval on June 20, 2023. It is approved for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

Suflave was approved by the FDA on June 15, 2023. It is a prescription laxative used to cleanse the bowel in preparation for colonoscopy in adults.

The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.

durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.